● Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 55% by 2020.
● Thanks to a sound financial situation, the firm has significant leeway for investment.
● The company shows low valuation levels, with an enterprise value at 0.47 times its sales.
● Analysts covering this company mostly recommend stock overweighting or purchase.
● The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
● The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 35.73 times its estimated earnings per share for the ongoing year.
● For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.